WCLC 2022 | FoRT 05-BEAT: comparing 1L atezolizumab vs atezolizumab + bevacizumab in PD-L1 high NSCLC

Federico Cappuzzo, MD, PhD, AUSL della Romagna-Ravenna, Ravenna, Italy, talks on the rationale behind the Phase III FoRT 05-BEAT (NCT03896074) study comparing atezolizumab versus atezolizumab plus as first-line treatment in patients with PD-L1 high advanced/metastatic non-small cell lung cancer (NSCLC). Strong preclinical evidence suggests that agents interfering with myeloid infiltrates can potentiate the efficacy of immunotherapy. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.